^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Veyonda (idronoxil)

    i
    Other names: NOX66, NOX-66, isoflavonoid based cancer therapeutic
    Associations

    News

    Trials
    Company:
    Noxopharm
    Drug class:
    Topoisomerase II inhibitor, XIAP antagonist, ENOX2 inhib, S1P receptor inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer (clinicaltrials.gov)
    P1, N=25, Completed, Noxopharm Limited | Phase classification: P1b --> P1
    Phase classification
    |
    Veyonda (idronoxil)
    over1year
    A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=21, Terminated, Noxopharm Limited | Phase classification: P1b/2a --> P1/2
    Phase classification • Metastases
    |
    ER (Estrogen receptor)
    |
    Veyonda (idronoxil)
    over2years
    A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=10, Terminated, Noxopharm Limited | Trial completion date: Aug 2023 --> May 2023 | Active, not recruiting --> Terminated; Slow recruitment
    Trial completion date • Trial termination
    |
    NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride • Veyonda (idronoxil)
    over2years
    A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=21, Terminated, Noxopharm Limited | Active, not recruiting --> Terminated; Slow Recruitment
    Trial termination • Metastases
    |
    ER (Estrogen receptor)
    |
    Veyonda (idronoxil)
    over2years
    A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Noxopharm Limited | N=34 --> 10 | Trial primary completion date: Jul 2023 --> May 2023
    Enrollment change • Trial primary completion date
    |
    NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride • Veyonda (idronoxil)
    over2years
    A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=21, Active, not recruiting, Noxopharm Limited | Recruiting --> Active, not recruiting | N=70 --> 21 | Trial completion date: Feb 2024 --> Aug 2023
    Enrollment closed • Enrollment change • Trial completion date • Metastases
    |
    ER (Estrogen receptor)
    |
    Veyonda (idronoxil)
    over2years
    A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Noxopharm Limited | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Jul 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride • Veyonda (idronoxil)
    over2years
    ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent cancer. (PubMed, J Adv Res)
    Tumor-intrinsic ENOX2 expression is associated with tumor phenotype and PFS in NPC. Targeting ENOX2 with IDX and cisplatin impose qualitative control of T-cell response by preferentially increasing immune cells infiltration, Tem differentiation and tumor suppression. We suggest that ENOX2 inhibition may be a promising therapeutic strategy to enhance the effects of chemotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cisplatin • Veyonda (idronoxil) • phenoxodiol (NV06)
    almost3years
    A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=70, Recruiting, Noxopharm Limited | N=100 --> 70 | Trial primary completion date: Oct 2022 --> Aug 2023
    Enrollment change • Trial primary completion date • Metastases
    |
    ER (Estrogen receptor)
    |
    Veyonda (idronoxil)
    almost4years
    A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=34, Recruiting, Noxopharm Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride • Veyonda (idronoxil)
    4years
    A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Noxopharm Limited
    Clinical • New P1 trial
    |
    NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride • Veyonda (idronoxil)
    4years
    A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=100, Recruiting, Noxopharm Limited | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    ER (Estrogen receptor)
    |
    Veyonda (idronoxil)